Here's another Nasdaq stock to short in consideration that there may be a correction coming. GLYC has printed the SRP shakeout up-down whipsaw that is so often a signal that the trend has changed (as we saw with Bitcoin recently). Strong bearish RSI divergence since much lower in the uptrend could be a big clue that this will have quite a tumble. And so I have...
Great move up today with great volume during a down day for the overall market.. This came up on my 39 week high scan today, but it also came up on my scan on 12/22/2023 when I bought some. I might add to my position if the market starts to behave itself!
$GLYC - small cap biotech stock tightening up after a huge run up
weekly chart of stock "glyc"....................................................
My Post-FDA Over-The-Weekend Watchlist: $GLYC $ONCT $ONCY $PIRS $AGEN All of these biotechs have phase one cancer treatment clinical-trial data releases this weekend. Based on my research, these are the ones that I think are most likely to release good data. Since they are all in phase one, it is likely that we see a gap up on Monday and a solid downtrend from...
Fundamental Analysis: GlycoMimetics, Inc. is a clinical-stage biotechnology company that focuses on developing glycomimetics that inhibit disease-related functions of carbohydrates. They are currently developing a treatment for hormone receptor-positive metastatic breast cancer . The drug, GMI-1359, has undergone phase one safety trials, and the data from these...
MACD cross and yesterday's candle closing over the 38% fib level is very bullish. Also, the proximity to the POC line (red) looks like a low-risk entry. Looking for $4.25, $4.44, and $4.72 in the short term.
Above its falling trendline, lets see if it holds
GLYC- Possible long here with stop at 5.24, Momentum play with first target at 7.83.
Huge area of support here. Will watch for a pull lower or a breakdown through 15.4
Buy the Dips here. Strong momentum and will break 26. Data release on their earnings date in early March provides a great entry opportunity. Would NOT be surprised to see this bought out either. $30 price target on a swing/ $50 by EOY
Break over downtrend with volume will look for entry.
THIS BIOTECH HAD A MONSTER MOVE FROM 5 TO 17 BEFORE COMING BACK TO EARTH. IT HAS SOME HIGH OCTANE PARTNERS LIKE PFIZER AND IS IN SEVERAL CLINICAL TRIALS. VOLUME DECLINED ON THE SELLOFF AND THE STOCK HAS BEEN RIDING THE 50 DAY m.a.AND JUST CLOSED ABOVE THE 13 DAY. THE OPTIONS HAVE ZERO OPEN INTEREST OR LIQUIDITY. i AM ALREADY LONG FROM $12 AND MISSED MY...
This one is on the verge of breaking the 9.00 level which has been a key level of resistance. If it breaks through, watch for a nice run.
Retest gap, so I'm looking to play a retest, buy at old resistance as new support. Already up .53R on the day thanks to $DE